

Maddalena Barba

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1940577/publications.pdf>

Version: 2024-02-01

124
papers

3,120
citations

172207

29
h-index

243296

44
g-index

124
all docs

124
docs citations

124
times ranked

4705
citing authors

#	ARTICLE	IF	CITATIONS
1	Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. The Cochrane Library, 2014, , CD006650.	1.5	152
2	Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives. Journal of Hematology and Oncology, 2019, 12, 111.	6.9	93
3	Triple positive breast cancer: A distinct subtype?. Cancer Treatment Reviews, 2015, 41, 69-76.	3.4	83
4	Thromboprophylaxis for patients with cancer and central venous catheters. Cancer, 2008, 112, 2483-2492.	2.0	81
5	Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies. Expert Review of Vaccines, 2016, 15, 1327-1336.	2.0	79
6	Low-Molecular-Weight Heparin vs Unfractionated Heparin for Perioperative Thromboprophylaxis in Patients With Cancer<subtitle>A Systematic Review and Meta-analysis</subtitle>. Archives of Internal Medicine, 2008, 168, 1261.	4.3	75
7	The Hippo transducers TAZ and YAP in breast cancer: oncogenic activities and clinical implications. Expert Reviews in Molecular Medicine, 2015, 17, e14.	1.6	75
8	Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. The Cochrane Library, 2023, 2023, CD006650.	1.5	65
9	Erythrocyte Membrane Phospholipid Composition as a Biomarker of Dietary Fat. Annals of Nutrition and Metabolism, 2006, 50, 95-102.	1.0	63
10	Extended perioperative thromboprophylaxis in patients with cancer. Thrombosis and Haemostasis, 2008, 100, 1176-1180.	1.8	63
11	Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma. Journal of Thoracic Oncology, 2019, 14, 1924-1934.	0.5	60
12	Parenteral anticoagulation in ambulatory patients with cancer. , 2014, , CD006652.		56
13	Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation. , 2007, , CD006652.		55
14	A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. Oncotarget, 2017, 8, 56921-56931.	0.8	53
15	Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. , 2011, , CD006652.		52
16	Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. The Cochrane Library, 2014, , CD006649.	1.5	52
17	Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a cochrane systematic review. Journal of Experimental and Clinical Cancer Research, 2008, 27, 21.	3.5	51
18	Emerging Biological Treatments for Uterine Cervical Carcinoma. Journal of Cancer, 2014, 5, 86-97.	1.2	51

#	ARTICLE	IF	CITATIONS
19	Vitamin D Supplementation and Breast Cancer Prevention: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. PLoS ONE, 2013, 8, e69269.	1.1	45
20	Molecular profiles of screen detected vs. symptomatic breast cancer and their impact on survival: results from a clinical series. BMC Cancer, 2013, 13, 15.	1.1	44
21	Parenteral anticoagulation in ambulatory patients with cancer. The Cochrane Library, 2023, 2023, CD006652.	1.5	42
22	Anticoagulation for people with cancer and central venous catheters. The Cochrane Library, 2014, , CD006468.	1.5	41
23	Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study. Breast Cancer Research and Treatment, 2014, 147, 599-607.	1.1	39
24	Parenteral anticoagulation may prolong the survival of patients with limited small cell lung cancer: a Cochrane systematic review. Journal of Experimental and Clinical Cancer Research, 2008, 27, 4.	3.5	37
25	The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy. Oncotarget, 2014, 5, 9619-9625.	0.8	35
26	The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer. Oncotarget, 2016, 7, 43188-43198.	0.8	35
27	Perinatal Exposures and Breast Cancer Risk in the Western New York Exposures and Breast Cancer (WEB) Study. Cancer Causes and Control, 2006, 17, 395-401.	0.8	34
28	Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Cancer, 2008, 113, 1685-1694.	2.0	33
29	Metformin, diet and breast cancer: An avenue for chemoprevention. Cell Cycle, 2009, 8, 2661-2661.	1.3	33
30	Wasting lives: The effects of toxic waste exposure on health. The case of Campania, Southern Italy. Cancer Biology and Therapy, 2011, 12, 106-111.	1.5	33
31	Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting. Journal of Cellular Physiology, 2018, 233, 2313-2323.	2.0	33
32	“Triple positive” early breast cancer: an observational multicenter retrospective analysis of outcome. Oncotarget, 2016, 7, 17932-17944.	0.8	33
33	Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer. Breast Cancer Research and Treatment, 2013, 141, 119-123.	1.1	32
34	Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer. The Cochrane Library, 2014, , CD009447.	1.5	32
35	Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: results from a pooled analysis. Journal of Hematology and Oncology, 2015, 8, 53.	6.9	32
36	Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study. Journal of Experimental and Clinical Cancer Research, 2020, 39, 279.	3.5	32

#	ARTICLE	IF	CITATIONS
37	The effects of metformin on endogenous androgens and SHBG in women: a systematic review and meta-analysis. <i>Clinical Endocrinology</i> , 2009, 70, 661-670.	1.2	30
38	Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. , 2011, , CD006650.		30
39	Analysis of the hippo transducers TAZ and YAP in cervical cancer and its microenvironment. <i>Oncolmmunology</i> , 2016, 5, e1160187.	2.1	30
40	DNA damage repair and survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy. <i>International Journal of Cancer</i> , 2017, 140, 2587-2595.	2.3	30
41	Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3528.	1.8	30
42	Equol Status Modifies the Association of Soy Intake and Mammographic Density in a Sample of Postmenopausal Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 33-42.	1.1	29
43	Anticoagulation for thrombosis prophylaxis in cancer patients with central venous catheters. , 2007, , CD006468.		28
44	An instrument to assess quality of life in relation to nutrition: item generation, item reduction and initial validation. <i>Health and Quality of Life Outcomes</i> , 2010, 8, 26.	1.0	28
45	Anticoagulation for people with cancer and central venous catheters. <i>The Cochrane Library</i> , 2019, 2019, CD006468.	1.5	28
46	Long-Term Safety and Real-World Effectiveness of Trastuzumab in Breast Cancer. <i>Journal of Clinical Medicine</i> , 2019, 8, 254.	1.0	27
47	Anticoagulation for the initial treatment of venous thromboembolism in people with cancer. <i>The Cochrane Library</i> , 2019, 2019, CD006649.	1.5	26
48	Oral anticoagulation for prolonging survival in patients with cancer. , 2007, , CD006466.		25
49	Antiandrogen therapy in metastatic male breast cancer: results from an updated analysis in an expanded case series. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 73-80.	1.1	24
50	Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 62.	3.5	24
51	FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 67.	3.5	22
52	Expression of phosphorylated Hippo pathway kinases (MST1/2 and LATS1/2) in HER2-positive and triple-negative breast cancer patients treated with neoadjuvant therapy. <i>Cancer Biology and Therapy</i> , 2017, 18, 339-346.	1.5	22
53	Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer. , 2008, , CD006650.		21
54	Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. , 2011, , CD006649.		21

#	ARTICLE	IF	CITATIONS
55	Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience. <i>Journal of Cellular Physiology</i> , 2019, 234, 7708-7717.	2.0	21
56	Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer. <i>Gastric Cancer</i> , 2014, 17, 718-724.	2.7	20
57	Estrogen Metabolism and Mammographic Density in Postmenopausal Women: A Cross-Sectional Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1582-1591.	1.1	19
58	Aromatase inhibitors for metastatic male breast cancer: molecular, endocrine, and clinical considerations. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 227-235.	1.1	19
59	Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence. <i>Journal of Cellular Physiology</i> , 2020, 235, 7900-7910.	2.0	19
60	Androgen receptor and antiandrogen therapy in male breast cancer. <i>Cancer Letters</i> , 2015, 368, 20-25.	3.2	17
61	Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation. <i>The Cochrane Library</i> , 2017, 12, CD006466.	1.5	17
62	GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancer. <i>Journal of Cellular Physiology</i> , 2018, 233, 1396-1401.	2.0	17
63	Urinary estrogen metabolites and prostate cancer: a case-control study and meta-analysis. <i>Journal of Experimental and Clinical Cancer Research</i> , 2009, 28, 135.	3.5	16
64	Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. , 2011, , CD006649.		16
65	Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study. <i>Scientific Reports</i> , 2017, 7, 10597.	1.6	16
66	A Real-World Multicentre Retrospective Study of Paclitaxel+Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer. <i>Journal of Cellular Physiology</i> , 2017, 232, 1571-1578.	2.0	16
67	Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting. <i>Journal of Translational Medicine</i> , 2018, 16, 129.	1.8	16
68	Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future Scenarios. <i>Journal of Cancer</i> , 2019, 10, 5903-5914.	1.2	16
69	Indicators of Sexual and Somatic Development and Adolescent Body Size in Relation to Prostate Cancer Risk: Results From a Case-Control Study. <i>Urology</i> , 2008, 72, 183-187.	0.5	15
70	Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 49.	3.5	15
71	Efficacy of chemotherapy in metastatic male breast cancer patients: a retrospective study. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 26.	3.5	15
72	Anticoagulation for perioperative thromboprophylaxis in people with cancer. <i>The Cochrane Library</i> , 2019, 2019, CD009447.	1.5	15

#	ARTICLE	IF	CITATIONS
73	Lifetime total and beverage specific - alcohol intake and prostate cancer risk: a case-control study. <i>Nutrition Journal</i> , 2004, 3, 23.	1.5	14
74	Analysis of the ATR-Chk1 and ATM-Chk2 pathways in male breast cancer revealed the prognostic significance of ATR expression. <i>Scientific Reports</i> , 2017, 7, 8078.	1.6	14
75	Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis. <i>Oncotarget</i> , 2015, 6, 42773-42780.	0.8	14
76	Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. , 2011, , CD006466.		13
77	Cancer mortality trends between 1988 and 2009 in the metropolitan area of Naples and Caserta, Southern Italy. <i>Cancer Biology and Therapy</i> , 2013, 14, 1113-1122.	1.5	13
78	Cancer stem cells: are they responsible for treatment failure?. <i>Future Oncology</i> , 2014, 10, 2033-2044.	1.1	13
79	Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. , 2014, , CD006466.		13
80	Metformin and breast cancer: Basic knowledge in clinical context. <i>Cancer Treatment Reviews</i> , 2015, 41, 441-447.	3.4	13
81	Expression of the Hippo transducer TAZ in association with WNT pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy. <i>Journal of Translational Medicine</i> , 2018, 16, 22.	1.8	13
82	Basal growth hormone concentrations in blood and the risk for prostate cancer: A case-control study. <i>Prostate</i> , 2005, 64, 109-115.	1.2	12
83	The burden of breast cancer in Italy: mastectomies and quadrantectomies performed between 2001 and 2008 based on nationwide hospital discharge records. <i>Journal of Experimental and Clinical Cancer Research</i> , 2012, 31, 96.	3.5	12
84	Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial. <i>Journal of Cellular Physiology</i> , 2016, 231, 2541-2547.	2.0	12
85	Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin. <i>Journal of Cellular Physiology</i> , 2016, 231, 986-991.	2.0	12
86	Body mass index modifies the relationship between γ -H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer. <i>BMC Cancer</i> , 2017, 17, 101.	1.1	12
87	Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab. <i>Cancer Biology and Therapy</i> , 2018, 19, 328-334.	1.5	12
88	Deep sequencing and pathway-focused analysis revealed multigene oncogene signatures predicting survival outcomes in advanced colorectal cancer. <i>Oncogenesis</i> , 2018, 7, 55.	2.1	12
89	Association between mode of breast cancer detection and diagnosis delay. <i>Breast</i> , 2009, 18, 382-386.	0.9	11
90	The clinical significance of PD-L1 in advanced gastric cancer is dependent on ARID1A mutations and ATM expression. <i>Oncolmmunology</i> , 2018, 7, e1457602.	2.1	11

#	ARTICLE	IF	CITATIONS
91	Iodixanol versus iopromide in cancer patients: Evidence from a randomized clinical trial. <i>Journal of Cellular Physiology</i> , 2018, 233, 2572-2580.	2.0	11
92	Palliative- and non-palliative indications for glucocorticoids use in course of immune-checkpoint inhibition. Current evidence and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103176.	2.0	11
93	DNA Damage and Repair Biomarkers in Cervical Cancer Patients Treated with Neoadjuvant Chemotherapy: An Exploratory Analysis. <i>PLoS ONE</i> , 2016, 11, e0149872.	1.1	11
94	p53 status as effect modifier of the association between pre-treatment fasting glucose and breast cancer outcomes in non diabetic, HER2 positive patients treated with trastuzumab. <i>Oncotarget</i> , 2014, 5, 10382-10392.	0.8	11
95	Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. , 2011, , CD006652.		10
96	Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial. <i>Oncotarget</i> , 2017, 8, 54528-54536.	0.8	10
97	MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNomics study. <i>Biomarker Research</i> , 2021, 9, 57.	2.8	10
98	Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. , 2008, , CD006649.		9
99	Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. , 2010, , CD006466.		9
100	Reducing the risk of overdiagnosis in lung cancer: A support from molecular biology. <i>Journal of Cellular Physiology</i> , 2011, 226, 2213-2214.	2.0	9
101	Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. , 2014, , CD006466.		9
102	Presurgical window of opportunity trial design as a platform for testing anticancer drugs: Pros, cons and a focus on breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 106, 132-142.	2.0	9
103	Association between AXL, Hippo Transducers, and Survival Outcomes in Male Breast Cancer. <i>Journal of Cellular Physiology</i> , 2017, 232, 2246-2252.	2.0	9
104	Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. , 2011, , CD006649.		8
105	HMG-CoAR expression in male breast cancer: relationship with hormone receptors, Hippo transducers and survival outcomes. <i>Scientific Reports</i> , 2016, 6, 35121.	1.6	6
106	Body mass index and treatment outcomes following neoadjuvant therapy in women aged 45Ây or younger: Evidence from a historic cohort. <i>Cancer Biology and Therapy</i> , 2016, 17, 470-476.	1.5	6
107	Coexisting YAP expression and TP53 missense mutations delineates a molecular scenario unexpectedly associated with better survival outcomes in advanced gastric cancer. <i>Journal of Translational Medicine</i> , 2018, 16, 247.	1.8	6
108	Cancer patients and coronavirus disease 2019: evidence in context. <i>Journal of Translational Medicine</i> , 2020, 18, 315.	1.8	6

#	ARTICLE	IF	CITATIONS
109	PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110598.	1.4	6
110	Anthropometric, Metabolic and Molecular Determinants of Human Epidermal Growth Factor Receptor 2 Expression in Luminal B Breast Cancer. <i>Journal of Cellular Physiology</i> , 2015, 230, 1708-1712.	2.0	5
111	Hot flushes in women with breast cancer: state of the art and future perspectives. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 185-198.	1.1	4
112	Metabolic Determinants and Anthropometric Indicators Impact Clinical-pathological Features in Epithelial Ovarian Cancer Patients. <i>Journal of Cancer</i> , 2016, 7, 516-522.	1.2	4
113	ESAS and FACT-B in eribulin-treated metastatic breast cancer patients: a multicenter, prospective and observational study. <i>Future Oncology</i> , 2017, 13, 1517-1525.	1.1	4
114	Indirect Basal Metabolism Estimation in Tailoring Recombinant Human TSH Administration in Patients Affected by Differentiated Thyroid Cancer: A Hypothesis-Generating Study. <i>Frontiers in Endocrinology</i> , 2018, 9, 37.	1.5	4
115	Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting. <i>International Journal of Cancer</i> , 2020, 146, 1917-1929.	2.3	4
116	Anticoagulation for the initial treatment of venous thromboembolism in people with cancer. <i>The Cochrane Library</i> , 2021, 2021, CD006649.	1.5	4
117	Is it Time to Test Metformin in Breast Cancer Prevention Trials? a Reply to the Authors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2565-2565.	1.1	3
118	Risk of SARS-CoV-2 infection and disease in metastatic triple-negative breast cancer patients treated with immune checkpoint inhibitors. <i>Immunotherapy</i> , 2020, 12, 675-679.	1.0	3
119	Mortality trend for liver cancer in a hyperendemic area of hepatitis C virus infection in southern Italy. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 245-246.	0.8	2
120	Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591985319.	1.4	2
121	Observational Multicenter Study on the Prognostic Relevance of Coagulation Activation in Risk Assessment and Stratification in Locally Advanced Breast Cancer. Outline of the ARIAS Trial. <i>Cancers</i> , 2020, 12, 849.	1.7	2
122	Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation. <i>The Cochrane Library</i> , 2021, 2021, CD006466.	1.5	2
123	Case report: 5-year progression free survival and complete liver response in a patient with metastatic breast cancer treated with everolimus plus exemestane. <i>Medicine (United States)</i> , 2020, 99, e21211.	0.4	1
124	Is there a role for adjuvant pertuzumab in HER2-positive breast cancer?. <i>Translational Cancer Research</i> , 2017, 6, S1281-S1284.	0.4	0